BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamamoto Y, Uemura M, Fujita M, Maejima K, Koh Y, Matsushita M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, Kinouchi T, Hayashi T, Matsuzaki K, Jingushi K, Kato T, Kawashima A, Ujike T, Nagahara A, Fujita K, Imamura R, Nakagawa H, Nonomura N. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Cancer Sci 2019;110:617-28. [PMID: 30536551 DOI: 10.1111/cas.13906] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, Dyrskjøt L, Kamat AM. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. European Urology Oncology 2021. [DOI: 10.1016/j.euo.2021.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang L, Lin Y, Yuan Y, Liu F, Sun K. Identification of TYROBP and FCER1G as Key Genes with Prognostic Value in Clear Cell Renal Cell Carcinoma by Bioinformatics Analysis. Biochem Genet 2021. [PMID: 33786672 DOI: 10.1007/s10528-021-10061-y] [Reference Citation Analysis]
3 Kim YJ, Kang Y, Kim JS, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Park D, Park WY, Kang M. Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma. Sci Rep 2021;11:5600. [PMID: 33692449 DOI: 10.1038/s41598-021-85099-4] [Reference Citation Analysis]
4 Cimadamore A, Gasparrini S, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. Cancers (Basel) 2019;11:E196. [PMID: 30736478 DOI: 10.3390/cancers11020196] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
5 Bacon JVW, Annala M, Soleimani M, Lavoie JM, So A, Gleave ME, Fazli L, Wang G, Chi KN, Kollmannsberger CK, Wyatt AW, Nappi L. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2020;18:322-331.e2. [PMID: 32046920 DOI: 10.1016/j.clgc.2019.12.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
6 Shi J, Zhang R, Li J, Zhang R. Size profile of cell-free DNA: A beacon guiding the practice and innovation of clinical testing. Theranostics 2020;10:4737-48. [PMID: 32308746 DOI: 10.7150/thno.42565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
7 Hayashi Y, Fujita K. A new era in the detection of urothelial carcinoma by sequencing cell-free DNA. Transl Androl Urol 2019;8:S497-501. [PMID: 32042630 DOI: 10.21037/tau.2019.08.26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cinque A, Capasso A, Vago R, Lee MW, Floris M, Trevisani F. The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now? Biomedicines 2022;10:90. [DOI: 10.3390/biomedicines10010090] [Reference Citation Analysis]
9 Henriksen TV, Drue SO, Frydendahl A, Demuth C, Rasmussen MH, Reinert T, Pedersen JS, Andersen CL. Error Characterization and Statistical Modeling Improves Circulating Tumor DNA Detection by Droplet Digital PCR. Clin Chem 2022:hvab274. [PMID: 35030248 DOI: 10.1093/clinchem/hvab274] [Reference Citation Analysis]
10 Lakshminarayanan H, Rutishauser D, Schraml P, Moch H, Bolck HA. Liquid Biopsies in Renal Cell Carcinoma-Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease. Front Oncol 2020;10:582843. [PMID: 33194717 DOI: 10.3389/fonc.2020.582843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Geertsen L, Koldby KM, Thomassen M, Kruse T, Lund L. Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature. European Urology Open Science 2022;37:27-35. [DOI: 10.1016/j.euros.2021.12.006] [Reference Citation Analysis]
12 Ponti G, Maccaferri M, Manfredini M, Micali S, Torricelli F, Milandri R, Del Prete C, Ciarrocchi A, Ruini C, Benassi L, Bettelli S, Kaleci S, Ozben T, Tomasi A. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis. Clin Chim Acta 2019;497:76-80. [PMID: 31301282 DOI: 10.1016/j.cca.2019.07.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
13 Glennon KI, Maralani M, Abdian N, Paccard A, Montermini L, Nam AJ, Arseneault M, Staffa A, Jandaghi P, Meehan B, Brimo F, Tanguay S, Rak J, Riazalhosseini Y. Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma. Cancers (Basel) 2021;13:5825. [PMID: 34830979 DOI: 10.3390/cancers13225825] [Reference Citation Analysis]
14 Underhill HR. Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology? Mol Diagn Ther 2021;25:389-408. [PMID: 34018157 DOI: 10.1007/s40291-021-00534-6] [Reference Citation Analysis]
15 Zhu C, Zhuang W, Chen L, Yang W, Ou WB. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Transl Lung Cancer Res 2020;9:111-38. [PMID: 32206559 DOI: 10.21037/tlcr.2020.01.09] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
16 Chen X, Wang L, Lou J. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review. Med Sci Monit 2020;26:e921040. [PMID: 32200389 DOI: 10.12659/MSM.921040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Nishida K, Nojima S, Yamamoto Y, Kato T, Hatano K, Ujike T, Nagahara A, Fujita K, Morimoto-Okazawa A, Iwahori K, Uemura M, Imamura R, Ohkura N, Morii E, Sakaguchi S, Wada H, Nonomura N. Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. Sci Rep 2020;10:6220. [PMID: 32277125 DOI: 10.1038/s41598-020-63060-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
18 Park JS, Lee HJ, Almujalhem A, Althubiany HH, A AA, Jang WS, Kim J, Lee SH, Rha KH, Ham WS. Prediction of High-Grade Clear Cell Renal Cell Carcinoma Based on Plasma mRNA Profiles in Patients with Localized Pathologic T1N0M0 Stage Disease. Cancers (Basel) 2020;12:E1182. [PMID: 32392781 DOI: 10.3390/cancers12051182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Lenaerts L, Tuveri S, Jatsenko T, Amant F, Vermeesch JR. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope? Acta Clin Belg 2020;75:9-18. [PMID: 31578135 DOI: 10.1080/17843286.2019.1671653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, Moch H. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Rev Mol Diagn 2020;20:141-50. [PMID: 31498685 DOI: 10.1080/14737159.2019.1665510] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
21 Mano R, Gopal N, Hakimi AA. The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions. Curr Opin Urol 2019;29:531-9. [PMID: 31313716 DOI: 10.1097/MOU.0000000000000663] [Reference Citation Analysis]
22 Smith CG, Moser T, Mouliere F, Field-Rayner J, Eldridge M, Riediger AL, Chandrananda D, Heider K, Wan JCM, Warren AY, Morris J, Hudecova I, Cooper WN, Mitchell TJ, Gale D, Ruiz-Valdepenas A, Klatte T, Ursprung S, Sala E, Riddick ACP, Aho TF, Armitage JN, Perakis S, Pichler M, Seles M, Wcislo G, Welsh SJ, Matakidou A, Eisen T, Massie CE, Rosenfeld N, Heitzer E, Stewart GD. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Med 2020;12:23. [PMID: 32111235 DOI: 10.1186/s13073-020-00723-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
23 Chen L, Abou-Alfa GK, Zheng B, Liu JF, Bai J, Du LT, Qian YS, Fan R, Liu XL, Wu L, Hou JL, Wang HY; PreCar Team. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res 2021;31:589-92. [PMID: 33589745 DOI: 10.1038/s41422-020-00457-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Yamamoto Y, Uemura M, Fujita M, Maejima K, Koh Y, Matsushita M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, Kinouchi T, Hayashi T, Matsuzaki K, Jingushi K, Kato T, Kawashima A, Ujike T, Nagahara A, Fujita K, Imamura R, Nakagawa H, Nonomura N. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Cancer Sci 2019;110:617-28. [PMID: 30536551 DOI: 10.1111/cas.13906] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
25 Ponti G, Maccaferri M, Percesepe A, Tomasi A, Ozben T. Liquid biopsy with cell free DNA: new horizons for prostate cancer. Crit Rev Clin Lab Sci 2021;58:60-76. [PMID: 32805148 DOI: 10.1080/10408363.2020.1803789] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
26 Koh Y, Nakano K, Katayama K, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M, Hayashi Y, Yamamoto Y, Kato T, Hatano K, Kawashima A, Ujike T, Imamura R, Yamaguchi R, Imoto S, Shiotsu Y, Nonomura N, Uemura M. Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. Int J of Urology. [DOI: 10.1111/iju.14816] [Reference Citation Analysis]
27 Okita K, Hatakeyama S, Naito S, Numakura K, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Nishiyama H, Ito A, Kojima Y, Habuchi T, Obara W, Tsuchiya N, Ohyama C. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study. Urol Oncol 2021;39:836.e11-7. [PMID: 34544649 DOI: 10.1016/j.urolonc.2021.08.015] [Reference Citation Analysis]
28 Nakano K, Yamamoto Y, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M, Koh Y, Hayashi Y, Wang C, Ishizuya Y, Kato T, Hatano K, Kawashima A, Ujike T, Fujita K, Nonomura N, Uemura M. Fragmentation of cell-free DNA is induced by upper-tract urothelial carcinoma-associated systemic inflammation. Cancer Sci 2021;112:168-77. [PMID: 33027843 DOI: 10.1111/cas.14679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Zeuschner P, Zaccagnino A, Junker K. [Biomarkers for renal cell tumours]. Aktuelle Urol 2021;52:452-63. [PMID: 34157774 DOI: 10.1055/a-1517-6259] [Reference Citation Analysis]
30 Huang J, Cai W, Cai B, Kong W, Zhai W, Zhang J, Chen Y, Chen S, Bai Y, Huang Y, Xue W. Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients. Front Oncol 2021;11:697219. [PMID: 34568025 DOI: 10.3389/fonc.2021.697219] [Reference Citation Analysis]
31 Sumiyoshi T, Yamasaki T, Takeda M, Mizuno K, Utsunomiya N, Sakamoto H, Nakamura E, Ogawa O, Akamatsu S. Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma. Cancer Sci 2021;112:3363-74. [PMID: 34009695 DOI: 10.1111/cas.14972] [Cited by in F6Publishing: 1] [Reference Citation Analysis]